SCHEMBL7013183

SCHEMBL7013183

c1ccc(Oc2ccc(-n3cccc3)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 7/20 0.55
TSHR P16473 1/20 0.55
MGLL Q99685 1/20 0.52
NR1H2 P55055 1/20 0.48
BAX Q07812 1/20 0.48
MAOA P21397 1/20 0.48
NTRK1 P04629 1/20 0.46
IGF1R P08069 1/20 0.46
FGFR1 P11362 1/20 0.46
NTRK3 Q16288 1/20 0.46
NTRK2 Q16620 1/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
VHL P40337 1/20 0.43
ELOC Q15369 1/20 0.43
ELOB Q15370 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
KDM4E B2RXH2 1/20 0.43
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10619141 0.83 LTA4H (0.50) LTA4HTSHRMGLLNR1H2BAX
SCHEMBL20253478 0.83 ALDH1A1 (0.58) LTA4HTSHRMAOAMEN1KMT2A
SCHEMBL20238867 0.81 KDM4E (0.39) LTA4HTSHRMGLLMEN1KMT2A
SCHEMBL7015795 0.78 CYP1A2 (0.59) LTA4HTSHRMGLLNR1H2BAX
SCHEMBL44284 0.77 KDM4E (0.50) TSHRMEN1KMT2AVHLELOC
SCHEMBL3893562 0.77 LTA4H (0.92) LTA4HTSHRNR1H2BAXMAOA
SCHEMBL22129853 0.77 LTA4H (0.92) LTA4HTSHRNR1H2BAXMAOA
SCHEMBL122719 0.77 LTA4H (0.92) LTA4HTSHRNR1H2BAXMAOA
SCHEMBL9212518 0.77 LTA4H (0.92) LTA4HTSHRNR1H2BAXMAOA
SCHEMBL435149 0.77 LTA4H (0.92) LTA4HTSHRNR1H2BAXMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167067-A1 PHOTOREDOX-CATALYZED DIRECT C-H FUNCTIONALIZATION OF ARENES UNIV NORTH CAROLINA CHAPEL HILL (US) 2023-06-01 US disclosed
US-20180148414-A1 PHOTOREDOX-CATALYZED DIRECT C-H FUNCTIONALIZATION OF ARENES THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2018-05-31 US disclosed
CN-1147492-C New metal protease inhibitors, its preparing method and their medicinal composition containing them ɪά��ʵ���� 2004-04-28 CN disclosed
EP-1065209-B1 Metalloprotease inhibitors, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2003-05-02 EP disclosed
US-6339092-B1 FOR THERAPY RHEUMATOID ARTHRITIS, ARTHROSIS, TUMOUR INVASION AND GROWTH, INCLUDING MALIGNANT SPREAD AND THE FORMATION OF METASTASES, ULCERATIONS, ATHEROSCLEROSIS ADIR ET COMPAGNIE (FR) 2002-01-15 US disclosed
EP-1065209-A1 Metalloprotease inhibitors, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 2001-01-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148414-A1 PHOTOREDOX-CATALYZED DIRECT C-H FUNCTIONALIZATION OF ARENES PPOX, AOC2, AOC3 LTA4H 1625/4885TSHR 2772/4885MGLL 4127/4885
US-20230167067-A1 PHOTOREDOX-CATALYZED DIRECT C-H FUNCTIONALIZATION OF ARENES PPOX, AOC2, AOC3 LTA4H 1625/4885TSHR 2772/4885MGLL 4127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.